Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
123.52
-0.01 (-0.01%)
At close: Jun 26, 2026, 4:00 PM EDT
123.75
+0.23 (0.19%)
After-hours: Jun 26, 2026, 6:58 PM EDT
Nuvalent Employees
Nuvalent had 228 employees as of December 31, 2025. The number of employees increased by 86 or 60.56% compared to the previous year.
Employees
228
Change (1Y)
86
Growth (1Y)
60.56%
Revenue / Employee
n/a
Profits / Employee
-$1,923,393
Market Cap
9.76B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 228 | 86 | 60.56% |
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Dec 31, 2021 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
NUVL News
- 4 days ago - GSK announces commencement of tender offer to acquire Nuvalent - TheFly
- 4 days ago - Nuvalent downgraded to Market Perform from Outperform at Bernstein - TheFly
- 12 days ago - Nuvalent Transcript: AGM 2026 - Transcripts
- 12 days ago - Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC - CNBC
- 17 days ago - Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - Reuters
- 18 days ago - Nuvalent downgraded to Neutral from Buy at Guggenheim - TheFly
- 18 days ago - Nuvalent downgraded to Neutral from Buy at UBS - TheFly
- 18 days ago - After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal - WSJ